SCHEMBL3570265

SCHEMBL3570265

Nc1cccc(Cc2ccc3c(c2)CC(=O)N3)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 2/20 0.49
CACNG8 Q8WXS5 2/20 0.49
SMYD3 Q9H7B4 1/20 0.47
AHR P35869 2/20 0.46
PARP1 P09874 1/20 0.46
PGR P06401 2/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
MAOB P27338 3/20 0.44
HTR1A P08908 3/20 0.44
DRD2 P14416 3/20 0.44
HTR2A P28223 3/20 0.44
ADRA1D P25100 1/20 0.44
ADRA1A P35348 1/20 0.44
ADRA1B P35368 1/20 0.44
TDP2 O95551 1/20 0.44
PDK2 Q15119 1/20 0.44
PDE3B Q13370 1/20 0.42
PDE3A Q14432 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3579629 0.89 TDP2 (0.47) GRIA1CACNG8SMYD3AHRPARP1
SCHEMBL3574516 0.87 AHR (0.50) GRIA1CACNG8SMYD3AHRPGR
SCHEMBL6904021 0.85 AHR (0.53) GRIA1CACNG8SMYD3AHRPGR
SCHEMBL22660 0.78 AHR (0.61) GRIA1CACNG8SMYD3AHRPGR
SCHEMBL10714806 0.78 TDP2 (0.69) GRIA1CACNG8AHRPGRTDP2
SCHEMBL260951 0.77 AHR (0.56) GRIA1CACNG8SMYD3AHRPGR
SCHEMBL30946048 0.77 MAOB (0.56) GRIA1CACNG8SMYD3AHRPGR
SCHEMBL8670836 0.76 AHR (0.59) GRIA1CACNG8SMYD3AHRPGR
Hydrochloric Acid SCHEMBL15206761 0.76 AHR (0.59) GRIA1CACNG8SMYD3AHRPGR
Bromide SCHEMBL9824774 0.76 AHR (0.59) GRIA1CACNG8SMYD3AHRPGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7749530-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-07-06 US disclosed
WO-2010075197-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2010-07-01 WO disclosed
US-7692005-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-04-06 US disclosed
US-20090208557-A1 Kinase inhibitors ALLERGAN, INC. 2009-08-20 US disclosed
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP disclosed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US disclosed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090208557-A1 Kinase inhibitors PTK2, MAP3K6, MAP3K20 GRIA1 1234/4885CACNG8 4062/4885SMYD3 3186/4885
US-20070032478-A1 Kinase Inhibitors ABL1, LCK, ERBB2 GRIA1 1721/4885CACNG8 3250/4885SMYD3 1968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.